ARVN
Arvinas IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$720.60M
P/E Ratio
—
EPS
$-1.14
Beta
1.98
52W High
$14.51
52W Low
$5.90
50-Day MA
$12.39
200-Day MA
$10.17
Dividend Yield
—
Profit Margin
-30.80%
Forward P/E
17.86
PEG Ratio
—
About Arvinas Inc
Arvinas, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development, and commercialization of therapies to break down disease-causing proteins. The company is headquartered in New Haven, Connecticut.
Fundamentals
| Revenue (TTM) | $262.60M |
| Gross Profit (TTM) | $262.60M |
| EBITDA | $-111.90M |
| Operating Margin | -755.00% |
| Return on Equity | -16.20% |
| Return on Assets | -7.94% |
| Revenue/Share (TTM) | $3.70 |
| Book Value | $6.83 |
| Price-to-Book | 1.60 |
| Price-to-Sales (TTM) | 2.74 |
| EV/Revenue | 0.0641 |
| EV/EBITDA | -1.62 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -84.00% |
| Shares Outstanding | $63.96M |
| Float | $55.35M |
| % Insiders | 8.18% |
| % Institutions | 86.68% |
Analyst Ratings
Consensus ($14.88 target)
2
Strong Buy8
Buy8
Hold1
SellData last updated: 4/7/2026